These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7123554)

  • 1. Toxicological aspects of feprazone, a new nonsteroidal anti-inflammatory drug.
    Koyama T; Izawa Y; Wada H; Makita T; Hashimoto Y; Enomoto M
    Toxicol Appl Pharmacol; 1982 Jun; 64(2):255-70. PubMed ID: 7123554
    [No Abstract]   [Full Text] [Related]  

  • 2. Inducing effect of feprazone on hepatic drug-metabolizing enzymes in man.
    Morita K; Shibata H; Ono T; Shimakawa H
    Eur J Clin Pharmacol; 1986; 31(1):117-8. PubMed ID: 3780819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal blood loss on phenylbutazone and feprazone.
    Macfarlane JD; Maisey MN; Grahame R; Burry HC
    Rheumatol Rehabil; 1976 May; 15(2):108-11. PubMed ID: 132693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feprazone: an inducer of the P450 II B family of proteins in the rat.
    Smith JN; Ayrton AD; Chown J; Lewis DF; Ioannides C
    J Biochem Toxicol; 1990; 5(1):9-12. PubMed ID: 2402005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-pressure liquid chromatographic feprazone determination in pharmaceutical formulations.
    Bonora A; Borea PA
    J Pharm Sci; 1979 Jun; 68(6):798-800. PubMed ID: 458589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic injury following feprazone therapy.
    Wiggins J; Scott DL
    Rheumatol Rehabil; 1981 Feb; 20(1):44-5. PubMed ID: 6452677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind trial of feprazone and phenylbutazone in acute gout.
    Reardon JA; Stockman A; Darlington LG; Scott JT
    Curr Med Res Opin; 1980; 6(7):445-8. PubMed ID: 6988172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feprazone: absence of hemolytic effects in glucose-6-phosphate dehydrogenase-deficient subjects.
    Meloni T; Forteleoni G; Serra M; Daniotti S; Negri L; Giuntini P; Canepa L; Gaetani GF
    J Clin Pharmacol; 1982; 22(8-9):418-20. PubMed ID: 7130431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effects of feprazone and phenylbutazone on testosterone hydroxylations in mouse hepatic microsomes.
    Morita K; Hayashi Y; Ono T; Shimakawa H
    Chem Pharm Bull (Tokyo); 1986 Jan; 34(1):214-20. PubMed ID: 3698130
    [No Abstract]   [Full Text] [Related]  

  • 10. Rectal administration of feprazone in healthy volunteers.
    Ferrari P; Montanari C; Sala P; Vidi A
    Br J Clin Pharmacol; 1976 Apr; 3(2):339-40. PubMed ID: 973970
    [No Abstract]   [Full Text] [Related]  

  • 11. Species differences in the metabolism of feprazone, an antiinflammatory drug.
    Gaetani M; Yamaguchi H; Vidi A; Hashimoto Y; Donetti A
    Pharmacol Res Commun; 1979 Sep; 11(8):719-30. PubMed ID: 515116
    [No Abstract]   [Full Text] [Related]  

  • 12. Renal failure complicating feprazone treatment.
    Robertson C; Innes S; Paton J
    Hum Toxicol; 1981; 1(1):71-2. PubMed ID: 6217146
    [No Abstract]   [Full Text] [Related]  

  • 13. [Gas chromatographic determination of Feprazone in medicinal preparations].
    Gallazzi A; Vanoni PC
    Farmaco Prat; 1975 Mar; 30(3):147-52. PubMed ID: 1204822
    [No Abstract]   [Full Text] [Related]  

  • 14. Feprazone compared with indomethacin in the management of rheumatoid arthritis.
    Sturrock R; Isaacs A; Hart FD
    Practitioner; 1975 Jul; 215(1285):94-7. PubMed ID: 1103113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Miscellaneous rheumatological conditions treated in monitored-release studies with feprazone.
    Harris PG
    J Int Med Res; 1981; 9(4):248-52. PubMed ID: 6973494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feprazone, a new anti-inflammatory agent. Studies of potency and gastrointestinal tolerance.
    Fletcher MR; Loebl W; Scott JT
    Ann Rheum Dis; 1975 Apr; 34(2):190-4. PubMed ID: 1094965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombocytopenia and haemolytic anaemia due to feprazone.
    Bell PM; Humphrey CA
    Br Med J (Clin Res Ed); 1982 Jan; 284(6308):17. PubMed ID: 6797620
    [No Abstract]   [Full Text] [Related]  

  • 18. The influence of aluminium hydroxide on the bioavailability of feprazone. Single dose study.
    Spahn H; Mutschler E
    Arzneimittelforschung; 1985; 35(1):167-9. PubMed ID: 4039147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Determination of feprazone and one of its metabolites in human plasma after high-performance liquid chromatographic or thin-layer chromatographic separation].
    Spahn H; Mutschler E
    J Chromatogr; 1982 Oct; 232(1):145-53. PubMed ID: 7142323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolites of feprazone in man.
    Yamaguchi H; Kubo J; Sekine K; Naruchi T; Hashimoto Y; Kato R
    Drug Metab Dispos; 1979; 7(5):340-4. PubMed ID: 40778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.